As I biked home from PlateletBio’s new offices in Watertown, MA, last March, I was excited about all we planned to accomplish in 2020. We had recently raised more than $80 million in venture funding and non-dilutive grants, built our own lab, and had ambitious plans for 2020. Read more >>
A donor-independent, on-demand emergency source of platelets is needed to serve as a medical countermeasure (MCM) for mass casualty incidents. See how BARDA is investing in Platelet Biogenesis’s advanced manufacturing platform to develop synthetic platelet-like cells. Read more >>
Platelet BioGenesis (PBG) reports that it is working with the Canadian Centre for Commercialization of Regenerative Medicine (CCRM) and GE Healthcare Life Sciences to develop customized media formulations that will enable efficient differentiation of stem cells to platelet-based treatments, thereby avoiding the reliance on blood donors in the future. Read more >>
There is a chronic global shortage of platelets to treat patients who are actively bleeding due to trauma or surgery, those undergoing treatments for cancer, or those with low platelet counts due to a variety of conditions – essentially anyone who needs to prevent life-threatening bleeding. Platelet BioGenesis (PBG) is working with CCRM and GE Healthcare Life Sciences to develop customized media formulations that will enable efficient differentiation of stem cells to platelet-based therapeutics, thereby avoiding the reliance on […]
Platelet Biogenesis, Inc. (PBG), the leader in stem cell-derived, on-demand human platelets (PLTs+™) and genetically engineered platelet-based therapeutics, announced today it received an award of $2.3 million from the Medical Technology Enterprise Consortium (MTEC) – a 501(c)(3) biomedical technology consortium collaborating with the U.S. Army Medical Research and Development Command (USAMRDC). Read more >>
The summer slump wore off in September with over 50 Boston startups raising north of a billion dollars in venture funding, including Platelet BioGenesis. Read more >>
The Department of Health and Human Services (HHS) has earmarked funds to aid the development of new technology that could bolster emergency preparedness by producing platelets outside the human body. If the two-year, $4.9 million agreement between HHS Biomedical Advanced Research and Development Authority (BARDA) and Platelet BioGenesis, Inc. (PBG) of Cambridge, Mass., produces the desired results, the technology would improve emergency preparedness by making additional blood products available to save lives during a radiological or nuclear emergency. Read […]
Boston-based Wasabi Technologies, Inc. has scored a partnership and an investment that will pave the cloud storage provider’s way to the Japanese market in a deal that serial entrepreneur and CEO David Friend called “the most important business deal we’ve done since starting the company.” Read more >>
Platelet BioGenesis Receives $56 Million Contract from the Biomedical Advanced Research and Development Authority (BARDA) to Develop Human Stem Cell-Derived Platelets as a Medical Countermeasure to Radiological and Nuclear Exposure. Read more >>
Platelet BioGenesis Inc. said Sept. 9 that it raised more than $26 million in a Series A round co-led by Ziff Capital Partners and Qiming Venture Partners USA. Read more >>
